Rhinomed Limited
RHNMF · OTC
12/30/2023 | 6/30/2023 | 12/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.02 | -0.01 | 0.10 |
| FCF Yield | -90.87% | -24.38% | -8.93% | -13.47% |
| EV / EBITDA | 0.00 | -3.80 | -7.60 | -13.05 |
| Quality | ||||
| ROIC | 0.00% | -85.90% | -86.87% | -46.95% |
| Gross Margin | 100.00% | 8.81% | -16.28% | 72.37% |
| Cash Conversion Ratio | – | 0.71 | 0.58 | 1.77 |
| Growth | ||||
| Revenue 3-Year CAGR | 48.10% | 45.02% | 53.50% | 51.00% |
| Free Cash Flow Growth | -59.53% | -63.65% | 34.73% | -76.61% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.37 | -0.26 | 0.72 |
| Interest Coverage | 0.00 | -19.99 | -66.63 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 3.00 | 2.90 | 1.26 |
| Cash Conversion Cycle | 0.00 | 21.54 | -7.73 | -48.90 |